We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BAC:NYSEBank of America Corporation Analysis

Data as of 2026-03-09 - not real-time

$47.01

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Bank of America (BAC) is trading at $47.00, near its 20‑day support of $46.78 and well below the 52‑week high of $57.55. The Relative Strength Index sits at 28, signaling an oversold condition, while the MACD remains bearish, suggesting short‑term momentum is still negative. Fundamentally, the stock trades at a forward P/E of 9.5 versus an industry average of 17.1, indicating a valuation discount, and it offers a 2.3% dividend yield with a modest 28% payout ratio, supporting dividend sustainability. The DCF‑derived fair value of roughly $23 is far below the market price, but the calculated upside/downside metric of +32.6% and hedge‑fund sentiment describing BAC as a “highly favored long‑term buy” point to perceived upside potential.
The balance sheet shows roughly equal cash and debt levels, a neutral beta (~1.0) and a 30% 30‑day volatility, implying market‑wide risk but not excessive company‑specific risk. Overall, the mix of technical oversold signals, attractive valuation multiples, solid dividend yield, and positive analyst consensus suggests a buying opportunity, especially for investors comfortable with medium‑term volatility.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • RSI indicating oversold conditions
  • Price near strong support level
  • Attractive dividend yield with low payout ratio

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward P/E well below industry average
  • Positive hedge‑fund sentiment and analyst consensus
  • Sustainable dividend and improving earnings outlook

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Stable dividend policy and solid ROE
  • Exposure to interest‑rate environment and regulatory landscape
  • Valuation discount provides margin of safety

Key Metrics & Analysis

Financial Health

Revenue Growth7.20%
Profit Margin28.40%
P/E Ratio12.3
ROE10.22%
ROA0.91%
P/B Ratio1.2
Op. Cash Flow$12.6B
Industry P/E17.1

Technical Analysis

TrendNeutral
RSI28.4
Support$46.78
Resistance$56.83
MA 20$51.67
MA 50$53.26
MA 200$50.52
MACDBearish
VolumeIncreasing
Fear & Greed Index100

Valuation

Fair Value$23.25
Target Price$62.35
Upside/Downside32.65%
GradeUndervalued
TypeBlend
Dividend Yield2.30%

Risk Assessment

Beta0.98
Volatility30.23%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.